Press release
Friedreich's Ataxia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, and others
(Albany, United States) As per DelveInsight's assessment, globally, the Friedreich's Ataxia pipeline constitutes 10+ key companies continuously working towards developing 10+ Friedreich's Ataxia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.In the Friedreich's Ataxia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Friedreich's Ataxia NDA approvals (if any), and product development activities comprising the technology, Friedreich's Ataxia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Friedreich's Ataxia pipeline treatment landscape of the report, click here @ Friedreich's Ataxia Pipeline- https://www.delveinsight.com/report-store/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Friedreich's Ataxia Pipeline Report
• DelveInsight's Friedreich's Ataxia Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Friedreich's Ataxia Companies working in the market include PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others
• Promising Friedreich's Ataxia Pipeline Therapies in the various stages of development include TAK-831, Omaveloxolone Capsules, 2.5 mg, MIN-102, Deferiprone oral solution 100mg/mL, MIB-626, Vatiquinone, DT-216, deferiprone, RT001, Idebenone, and others.
• On July 2023, Metro International Biotech LLC announced a study of phase 2 clinical trials for MIB-626. The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%. A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle bioenergetics.
• On July 2023, PTC Therapeutics announced a study of phase 3 clinical trials for Vatiquinone. The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone in Study PTC743-NEU-003-FA (NCT04577352) or Study PTC743-NEU-005-FA.
• On March 2023, Design Therapeutics Inc announced a study of phase 1 clinical trials for DT-216. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.
Friedreich's Ataxia Overview
Friedreich's Ataxia (FRDA) is a genetic, progressive, neurodegenerative movement disorder, with a typical age of onset between 10 and 15 years. Initial symptoms may include unsteady posture, frequent falling, and progressive difficulty in walking due to impaired ability to coordinate voluntary movements (ataxia).
To explore more information on the latest breakthroughs in the Friedreich's Ataxia Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Friedreich's Ataxia Emerging Drugs Profile
• RT 001: Retrotope
• Leriglitazone: Minoryx Therapeutics
Friedreich's Ataxia Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the Friedreich's Ataxia. The Friedreich's Ataxia companies which have their Friedreich's Ataxia drug candidates in the most advanced stage, i.e. Phase III include, Retrotope.
Request a sample and discover the recent advances in Friedreich's Ataxia Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Friedreich's Ataxia Drugs and Companies
• TAK-831: Neurocrine Biosciences
• Omaveloxolone Capsules, 2.5 mg: Reata Pharmaceuticals Inc
• MIN-102: Minoryx Therapeutics S.L.
• Deferiprone oral solution 100mg/mL: ApoPharma
• MIB-626: Metro International Biotech LLC
• Vatiquinone: PTC Therapeutics
Friedreich's Ataxia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Friedreich's Ataxia Therapeutics Market include-
PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others.
Dive deep into rich insights for drugs for Friedreich's Ataxia Pipeline, click here for Friedreich's Ataxia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Friedreich's Ataxia Pipeline Report
• Coverage- Global
• Friedreich's Ataxia Companies- PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, LEXEO Therapeutics, Exicure, StrideBio, Voyager Therapeutics, Lacerta Therapeutics, and others.
• Friedreich's Ataxia Pipeline Therapies- TAK-831, Omaveloxolone Capsules, 2.5 mg, MIN-102, Deferiprone oral solution 100mg/mL, MIB-626, Vatiquinone, DT-216, deferiprone, RT001, Idebenone, and others.
• Friedreich's Ataxia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Friedreich's Ataxia Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/friedreich-ataxia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Friedreich's Ataxia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Friedreich's Ataxia- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Friedreich's Ataxia Collaboration Deals
9. Late Stage Products (Phase III)
10. RT 001: Retrotope
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Leriglitazone: Minoryx Therapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. CTI-1601: Larimar Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. LX-2006: LEXEO Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Friedreich's Ataxia Key Companies
23. Friedreich's Ataxia Key Products
24. Friedreich's Ataxia- Unmet Needs
25. Friedreich's Ataxia- Market Drivers and Barriers
26. Friedreich's Ataxia- Future Perspectives and Conclusion
27. Friedreich's Ataxia Analyst Views
28. Friedreich's Ataxia Key Companies
29. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Friedreich's Ataxia Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, Larimar Therapeutics, and others here
News-ID: 3140387 • Views: …
More Releases from DelveInsight Business Research
Autism Spectrum Disorders Market Trends Point to Steady Growth Ahead by 2034, De …
DelveInsight's "Autism Spectrum Disorders Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Autism Spectrum Disorders, historical and forecasted epidemiology as well as the Autism Spectrum Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Autism Spectrum Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autism Spectrum Disorders…
Pulmonary Sarcoidosis Market Dynamics Indicate Upward Trajectory Through 2032, R …
The Pulmonary Sarcoidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Sarcoidosis pipeline products will significantly revolutionize the Pulmonary Sarcoidosis market dynamics.
DelveInsight's "Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Pulmonary Sarcoidosis, historical and forecasted epidemiology as well as the Pulmonary Sarcoidosis market trends in the United…
Prader-Willi Syndrome Market to Experience Notable Growth in Forecast Span by 20 …
DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Prader-Willi Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prader-Willi Syndrome pipeline…
Aspergillosis Pipeline 2025: Key Developments, Emerging Therapies, and Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Aspergillosis pipeline constitutes 10+ key companies continuously working towards developing 12+ Aspergillosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Aspergillosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Aspergillosis Market.
The Aspergillosis Pipeline report embraces in-depth…
More Releases for Friedreich
Friedreich Ataxia Marketed And Pipeline Drugs Analysis During the Forecast Perio …
The Friedreich's Ataxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Friedreich's Ataxia pipeline products will significantly revolutionize Friedreich's Ataxia market dynamics.
DelveInsight's "Friedreich's Ataxia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Friedreich's Ataxia, historical and forecasted epidemiology as well as the Friedreich's Ataxia market trends in the United States,…
Australian Friedreich Ataxia Therapeutics Market Report with Executive Summary, …
Report Overview
The Australian Friedreich Ataxia (FRDA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Friedreichs Ataxia (FRDA) is the common inherited ataxia in the Australian. FRDA is a genetic, progressive, neurodegenerative movement disorder, that primarily affects the nervous system and the heart with a typical age of onset between…
United Kingdom Friedreich Ataxia Therapeutics Market Report with Executive Summa …
Report Overview
The UK Friedreich Ataxia (FRDA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Friedreichs ataxia (FRDA) is the most common inherited ataxia in the UK. FRDA is a genetic, progressive, neurodegenerative movement disorder, that primarily affects the nervous system and the heart with a typical age of onset…
Friedreich Ataxia Market Analysis By Drug Class(ACE Inhibitors, Beta Blockers, D …
The global Friedreich's Ataxia market size was valued at USD 750 million in 2021 and is projected to reach around USD 2,060 million in 2030 exhibiting a CAGR of 12% in the forecasted period.
The fast research and development activities for manufacturing latest therapeutics for Friedreich's Ataxia treatment, rising inorganic business growth strategies such as acquisitions, collaborations, and others among market players, are expected to upsurge the market growth. However, problems…
Friedreich Ataxia Drug Market to Witness Growth Acceleration | Adverum Biotechno …
Friedreich Ataxia Drug Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report answers questions on the current and future technological advancements and development. It delivers an analysis of main manufactures and geographic regions.
The global Friedreich Ataxia Drug market is segmented by company, region (country), type, application, players, stakeholders, and others. The report includes the opportunities and encounters that are faced by…
Friedreich Ataxia Drug Market Emerging Trends || Leading Players are Edison Phar …
The market study on the global Friedreich Ataxia Drug Market will include the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2026, at the global level and across the major regions mentioned above.…
